Study designs of evaluations included in the review
Randomised controlled trials (RCTs) were included in the review.
Specific interventions included in the review
All trials using antibiotics effective against C. pneumoniae for the secondary prevention of IHD were eligible for inclusion. The antibiotics azithromycin, roxithromycin, metronidazole, omeprazole and clarithromycin, in varying doses, were included in the review. Studies were not excluded based on the presence or absence of C. pneumoniae testing.
Participants included in the review
Studies of patients with known IHD were eligible for inclusion. The included trials were of patients with known IHD and seropositivity to C. pneumoniae, unstable angina or acute myocardial infarction (MI) (non-Q wave), acute MI, acute coronary syndrome (ACS), or a history of MI and seropositivity to C. pneumoniae; patients admitted for acute MI or ACS; and male survivors of acute MI with seropositivity to C. pneumoniae. There appeared to have been an over-representation of men in the included studies (80.1%).
Outcomes assessed in the review
Studies that analysed IHD outcomes were eligible for inclusion. Clinical coronary events and death were included. Coronary events included acute MI, unstable angina, or sudden death.
How were decisions on the relevance of primary studies made?
The authors did not state how the papers were selected for the review, or how many reviewers performed the selection.